Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Bone erosions are a common manifestation and feature of structural damage in severe/chronic
tophaceous gout. Management of this destructive and often debilitating gout complication has
focused exclusively on urate-lowering therapy (ULT) to reduce frequency of gout attacks, but
little attention has been given to prevention or reversal of gout related bone erosions and
other structural damage to bone caused by gout. Since there is no known effective treatment
to attenuate or improve structural damage caused by gout, we propose a pilot, controlled,
proof-of-concept study in which denosumab, an FDA approved medication for the treatment of
bone loss, will be added to standard ULT in 20 patients with erosive gout.